SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

LBRX

LB Pharmaceuticals Inc.
NASDAQHealth Care

Latest close: 36.74 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Sep 15, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Sep 3, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  3. Aug 11, 2026Quarterly report · 10-QFiled by the company itself.Open the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record11728 flagged findings
Reported transactions (Form 4)51since Sep 10, 2025 · and 32 other holdings
Corporate events (8-K)10since Nov 13, 2025

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-08-11share offering or dilution eventfreshOpen filing ↗
    “…of $70.7 million, and negative cash flows from operations of $60.9 million. The Company has incurred net losses and negative cash…”
    +1 more passage from the same document
    • “…operations of $60.9 million. The Company has incurred net losses and negative cash flows from operations since its inception and…”
  • 2026-08-11listing compliance noticefreshOpen filing ↗
    “…stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore…”
    +1 more passage from the same document
    • “…our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to…”
  • 2026-08-11capital return (buybacks/dividends)freshOpen filing ↗
    “…December 31, 2025 if incurred in the United States (though the requirement to amortize foreign research and experimental expenses…”
  • 2026-08-11Department of Justice inquiryfreshOpen filing ↗
    “…(such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability…”
  • 2026-08-11reverse splitfreshOpen filing ↗
    “…million. Immediately prior to the IPO closing, all of the outstanding shares of the Company’s redeemable convertible preferred stock…”
    +1 more passage from the same document
    • “…the Company’s redeemable convertible preferred stock automatically converted into an aggregate of 3,191,334 shares of the Company’s…”
  • 2026-08-11share offering or dilution eventfreshOpen filing ↗
    “…$ 70.7 million , and negative cash flows from operations of $ 60.9 million . The Company has incurred net losses and negative cash…”
    +1 more passage from the same document
    • “…operations of $ 60.9 million . The Company has incurred net losses and negative cash flows from operations since its inception and…”
  • 2026-08-11listing compliance noticefreshOpen filing ↗
    “…stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore…”
    +1 more passage from the same document
    • “…our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to…”
  • 2026-08-11capital return (buybacks/dividends)freshOpen filing ↗
    “…December 31, 2025 if incurred in the United States (though the requirement to amortize foreign research and experimental expenses…”

2 older entries not shown

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 117)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Insider transaction · 2 Form 4 filings newshow all 2hide
  • Oct 13, 26SCHEDULE 13G/A ↗Passive stake · JPMORGAN CHASE & CO. · 4.3% · event on Sep 30, 26 · amendment new
  • Oct 1, 26POS AM ↗Securities offering
  • Oct 1, 26S-3ASR ↗Securities offering
  • Sep 24, 26Form 3 ↗Insider transaction
  • Sep 15, 26424B3 ↗Securities offering
  • Sep 15, 268-K ↗Current report · A senior executive left or was appointed
  • Sep 14, 26Form 3 ↗Insider transaction
  • Sep 3, 26424B3 ↗Securities offering
  • Sep 3, 268-K ↗Current report · A senior executive left or was appointed
  • Aug 14, 26SCHEDULE 13G/A ↗Passive stake · TCG Crossover GP II, LLC · 5.0% · event on Jun 30, 26 · amendment
  • Aug 11, 26424B3 ↗Securities offering
  • Aug 11, 2610-Q ↗Quarterly report
  • Aug 11, 268-K ↗Current report · Results
  • Aug 3, 26Form 4 ↗Insider transaction
  • Jul 29, 26SCHEDULE 13G/A ↗Passive stake · BlackRock, Inc. · 6.3% · event on Jun 30, 26 · amendment
  • Jul 29, 26424B3 ↗Securities offering
  • Jul 29, 268-K ↗Current report · Entered a material agreement
  • Jul 22, 26424B3 ↗Securities offering
  • Jul 22, 268-K ↗Current report · Other events
  • Jul 16, 26SCHEDULE 13G ↗Passive stake · JPMORGAN CHASE & CO · 5.2% · event on Jun 30, 26
  • Jun 10, 26424B3 ↗Securities offering
  • Jun 10, 268-K ↗Current report · A senior executive left or was appointed
  • Jun 9, 26Form 144 ↗Notice of proposed sale

117 filings on record, the oldest from Jun 17, 24.

Listing the 25 most recent filings of the 117 on record.

8-Ks, explained

Structure5Governance5
  • Sep 15, 26GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Sep 3, 26GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Jul 29, 26StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗
  • Governance3 senior executive changes2026show all 3hide
    • Jun 10, 26GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
    • Mar 16, 26GovernanceA senior executive left or was appointed8-K 5.02 ↗
    • Mar 10, 26GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Feb 5, 26StructureEntered a material agreement+4 more in the same filing8-K 1.01 ↗
  • Nov 13, 25StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13D: stake and stated purpose

Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.

  • Deep Track Capital, LP14.9%Sep 12, 25SCHEDULE 13D ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • Pontifax Management 4 G.P. (2015) Ltd.6.3%Sep 12, 25SCHEDULE 13D ↗4 co-filers on this document — the figure is the largest single stake, not their sum.

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • RA Capital Management, L.P.8.7%Dec 31, 25SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • Commodore Capital LP6.8%Mar 31, 26SCHEDULE 13G/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum.
  • BlackRock, Inc.6.3%Jun 30, 26SCHEDULE 13G/A ↗1 earlier filing
  • TCG Crossover GP II, LLC5.0%Jun 30, 26SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
  • Caligan Partners LP5.0%Mar 31, 26SCHEDULE 13G ↗2 co-filers on this document — the figure is the largest single stake, not their sum.
show 3 more holdershide
  • Trails Edge Capital Partners, LP5.0%Dec 24, 25SCHEDULE 13G ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
  • JPMORGAN CHASE & CO.4.3%Sep 30, 26SCHEDULE 13G/A ↗3 earlier filings
  • BlackRock Portfolio Management LLC3.8%Dec 31, 25SCHEDULE 13G/A ↗1 earlier filing

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Sep 12, 25Buy$5.0MVida Ventures GP III, L.L.C.↗
  • Sep 12, 25Buy$12KVida Ventures GP III, L.L.C.↗
  • Sep 12, 25Buy$15.0MRan Nussbaum↗
  • Sep 12, 25Buy$15.0MPontifax Management 4 G.P. (2015) Ltd.↗
  • Sep 12, 25Buy$30.0MDeep Track Biotechnology Master Fund, Ltd.↗
  • Sep 12, 25Buy$10.0MDeep Track Biotechnology Master Fund, Ltd.↗
Stock compensation, tax and giftsshow the 5 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Sep 12, 25Otheramount n/aVida Ventures GP III, L.L.C.↗
  • Sep 12, 25Otheramount n/aVida Ventures GP III, L.L.C.↗
  • Sep 12, 25Otheramount n/aRan Nussbaum↗
  • Sep 12, 25Otheramount n/aPontifax Management 4 G.P. (2015) Ltd.↗
  • Sep 12, 25Otheramount n/aDeep Track Biotechnology Master Fund, Ltd.↗

The full record holds 11 transactions and goes back to Sep 10, 25.

Its sector and its market

LB Pharmaceuticals Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From LB Pharmaceuticals Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow LB Pharmaceuticals Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
250 clean closes in the period.
SEC records
117 documents on file, from Jun 17, 2024 to Oct 13, 2026.
Company description
No description available.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.